Drugs / 23ME-00610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05199272 | Dec 2021 → Mar 2025 overdue | clear cell renal carcinoma, fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma +1 | 23andMe, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23ME-00610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199272 ↗ |
| Action | Inhibit | “23ME-00610 inhibits CD200R1 signaling” PMID 39651931 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity...” PMID 39651931 ↗ Jan 2025 |
| Route | Intravenous | “23ME-00610 given by IV infusion” NCT05199272 ↗ |
| Target | CD200R1 | “23ME-00610 inhibits CD200R1 signaling” PMID 39651931 ↗ Jan 2025 |